Learning Objectives for the Last-Chance Ambulatory Care Pharmacy Review

Webinar

Thursday, September 8, 2011

Biostatistics
Kevin Sowinski, Pharm.D., FCCP
Professor of Pharmacy Practice, Purdue University College of Pharmacy
Adjunct Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana

By the end of this presentation, participants should be able to:
1. For statistical tests commonly encountered in the pharmacotherapy literature, describe their appropriate application and interpretation.
2. Differentiate observational and controlled trial designs based upon their strengths and weaknesses (e.g., susceptibility to bias/confounding, ability to show causation, cost).
3. Detect common hazards in presenting and interpreting the statistical results of various trial types.

Hypertension/Dyslipidemia
Karen J. McConnell, Pharm.D., BCPS
Clinical Pharmacy Specialist, Clinical Pharmacy Cardiac Risk Service (CPCRS)
Clinical Associate Professor, School of Pharmacy
University of Colorado Denver
Aurora, Colorado

By the end of this presentation, participants should be able to:
1. Develop, implement and monitor detailed medication plans for dyslipidemia based on evidence-based and case-specific information.
2. Briefly discuss recent FDA advisory impacting simvastatin use in the United States.
3. Develop, implement and monitor detailed medication plans for hypertension based on evidence-based and case-specific information.
**Friday, September 9, 2011**

**Obstetrics/Gynecology**  
Alicia B. Forinash, Pharm.D., BCPS  
*Associate Professor of Pharmacy Practice*  
*St. Louis College of Pharmacy*  
*St. Louis, Missouri*

By the end of this presentation, participants should be able to:

1. Recommend appropriate therapy for contraception, emergency contraception, infertility, osteoporosis, and postmenopausal therapy.
2. Select appropriate therapy for drug therapy during pregnancy.
3. Explain factors that relate to drug therapy choices in pregnancy and lactation.
4. Educate patients and health care professionals regarding medication use during pregnancy and lactation.

**Infectious Diseases**  
Elizabeth A. Coyle, Pharm.D.  
*Clinical Associate Professor of Infectious Diseases*  
*University of Houston College of Pharmacy; Adjunct Assistant Professor*  
*Department of Infectious Diseases, Infection Control and Employee Health,*  
and *Director of the Infectious Diseases Pharmacy Residency at the University of Texas M.D. Anderson Cancer Center*  
*Houston, Texas*

By the end of this presentation, participants should be able to:

1. Based on the evidence based guidelines, participants should be able to design appropriate treatment regimens, pharmacologic and non-pharmacologic, for various patient populations with urinary tract infections, community-acquired pneumonia, upper respiratory tract infections, skin and soft tissue infections, and sexually transmitted diseases.
2. Identify risk factors and clinical circumstances in which antimicrobial resistance is a risk, and be able to appropriately design antimicrobial regimens to treat resistant infections and prevent future development.
3. Be able to apply patient and clinical factors to design antimicrobial regimens that are appropriate, increase compliance and are cost-effective for the patient.